Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/27/2010

on on Sunday October 31st. Authors of the study are Lawitz, E. et al.

Abstract 1861"Clinical synergy of an Anti-HCV Nucleotide Analog with SOC: Viral Kinetics of PSI-7977 with SOC" will be presented in a poster session on Tuesday November 2nd. Authors of the study are Lawitz E, et al.

Abstract 815"IL28B SNP Geographical Distribution and Antiviral Responses in a 28-day Phase 2a Trial of PSI-7977 Daily Dosing plus PEG-IFN/RBV" will be presented in a poster session on Sunday October 31st. Authors of the study are McHutchison, J.G. et al.

PSI-938Abstract 1890"Pharmacokinetics, Safety, and Tolerability of PSI-938, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Subjects" will be presented in a poster session on Tuesday November 2nd. Authors of the study are Symonds, W. et al.

About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog presently in a Phase 2b study, and PSI-938, a
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Present at the JMP Healthcare Conference
2. Pharmasset to Present at the UBS Global Life Sciences Conference
3. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
4. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2009 Financial Results
6. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
7. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
10. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
11. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  Over 200 runners participated in the fifth annual ... Oncology Institute (ROI), hosted by Radiation Business Solutions. This year ... San Francisco.  "Donations are still coming ... Business Solutions, "but at this point, through registrations ... the ROI this year. This surpasses last year,s record ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... , , AUSTIN, Texas, Sept. ... be at the forefront of ending Paralysis. WillWalk will raise $3 million ... with Spinal Cord Injury (SCI). , , The money ... U.S. The stem cells being used are a non-controversial adult stem cell ...
... , , SAN DIEGO, Sept. ... studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza ... (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, ... at the Centers for Disease Control and Prevention (CDC), University ...
Cached Medicine Technology:Paralyzed Artist Launches WillWalk Foundation to Cure Paralysis with Breakthrough Stem Cell Research 2NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 2NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 3
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, led ... the latest addition to their treatment options for ... dental implants. Often referred to as the “gentle ... factor normally associated with traditional gum surgery. No ... this procedure a very attractive oral surgery alternative ...
(Date:9/19/2014)... wonder material graphene has been used to detect molecules ... , The biosensor has been shown to be more ... in use, and was able to provide results in ... a rapid, point-of-care diagnostic tool for patients. , The ... Publishing,s journal 2D Materials . , To develop ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... a traditional Scandinavian style of eating, is ... Much like Diet Doc’s medical weight ... cooking and eating good food which leads ... focuses on teaching patients to understand how ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Activz Whole-Food ... Greens Smoothie product, a new whole-food produce powder ... in Baltimore, MD. Activz Greens Smoothie is ... in one convenient – and absolutely delicious —Greens Smoothie. ... in Baltimore, MD. , The new ...
(Date:9/19/2014)... QUT Centre for Accident Research & Road Safety - ... Safety in Transport Conference (OSIT) which is being held ... Ross Blackman, a CARRS-Q road safety researcher, said speed ... speed limits and related traffic controls remained in place ... wolf. If people are asked to slow down at ...
Breaking Medicine News(10 mins):Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2
... new bladder cancer therapy show promising interim results. Lead ... drug Urocidin follows thirty years of his research in ... results of the trial," says Dr. Morales, professor emeritus ... director of the Queen,s University Centre for Applied Urological ...
... crashes each year. As a result, most states have put laws ... cell phones and PDAs while driving. But a new study led ... distracted driving and the laws being passed to address the problem. ... Journal of Preventive Medicine , is the first comprehensive collection and ...
... improve their outcomes if they walk briskly for at least ... recent study in Cancer Research , a journal of ... that men who walk briskly after their diagnosis may delay ... Erin Richman, Sc.D., a research associate at the University of ...
... MA May 24, 2010 CardioCareLive, the world,s ... Johns Hopkins University School of Medicine, today announced ... to be held over two days on Tuesday ... of interest to cardiovascular care and internal medicine ...
... 24, 2011 The latest episode in the ... Global Challenges/Chemistry Solutions ," focuses on new blood ... infected with an antibiotic-resistant bacterium that,s become a ... "superbug" is called methicillin-resistant Staphylococcus aureus, or simply ...
... , TUESDAY, May 24 (HealthDay News) -- Rain-making bacteria ... particles play in the Earth,s precipitation cycle, new research ... at the general meeting of the American Society for ... within the center of hailstones, suggesting that airborne microorganisms ...
Cached Medicine News:Health News:New made-in-Canada therapy for bladder cancer shows promising results 2Health News:Temple-led study finds widening gap between distracted driving and legislation 2Health News:Brisk walking could improve prostate cancer outcomes 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 3Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Airborne Germs May Spur Rain, Snow, Hail 2
Intermittent catheter...
Intermittent catheter...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
... Welcome to a new dimension ... a liquid tool composed of purified ... surgical capabilities. Perfluoron is ideal for ... vitreoretinopathy, giant retinal tears and trauma. ...
Medicine Products: